David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...

A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...

The basis of peptide vaccination is the observation that leukemia cells can act as antigen-presenting cells (APCs) that cleave endogenous leukemia antigens in their proteasome and present them on ...

Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

These quiz questions about acute myeloid leukemia (AML) are derived from current literature. Are you up to date? At the end of the quiz, compare your score with those of your physician colleagues.

Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...